Download PDF
Pharmacopsychiatry 2009; 42(1): 14-19
DOI: 10.1055/s-0028-1085438
Original Paper

© Georg Thieme Verlag KG Stuttgart · New York

Rosiglitazone in the Assistance of Metabolic Control during Olanzapine Administration in Schizophrenia: A Pilot Double-blind, Placebo-controlled, 12-week Trial

T. Baptista 1 , N. Rangel 2 , Y. El Fakih 3 , E. Uzcátegui 3 , T. Galeazzi 4 , S. Beaulieu 5 , E. Araujo de Baptista 6
  • 1Department of Physiology, Los Andes University Medical School, Mérida, Venezuela
  • 2Psychiatric Institute “Dr. Raúl Castillo”, Peribeca, San Cristóbal, Táchira State, Venezuela
  • 3Department of Psychiatry, Los Andes University Medical School, Mérida, Venezuela
  • 4LABIMET, Los Andes University Medical School, San Cristóbal, Venezuela
  • 5Douglas Hospital Research Center, McGill University, Montreal, QC, Canada
  • 6Pharmacy School, Department of Microbiology, Los Andes University Medical School, Mérida, Venezuela
Further Information

Publication History

received 05.05.2008 revised 13.06.2008

accepted 09.07.2008

Publication Date:
19 January 2009 (online)

Also available at
    Permissions and Reprints

Abstract

Introduction: Excessive body weight gain (BWG), hyperglycemia and dyslipidemia are important side effects of olanzapine. We assessed the effects of rosiglitazone on BWG, the insulin resistance index (HOMA-IR), lipids, glycated hemoglobin and fibrinogen in olanzapine-treated schizophrenia patients.

Methods: Thirty patients taking olanzapine (10–20 mg daily for 8 months) were randomly allocated to rosiglitazone (n=15; 4 to 8 mg daily) or placebo (n=15) in a 12-week double-blind protocol. Anthropometric and biochemical variables were evaluated at baseline, weeks 6 and 12.

Results: The rosiglitazone and placebo groups gained 3.2±4.5 and 2.2±2.3 kg, respectively (p=0.65). Insulin and the HOMA-IR significantly decreased after rosiglitazone (p<0.05). Rosiglitazone did not improve the lipid profile, fibrinogen and Hb1c levels.

Discussion: The positive impact of rosiglitazone was limited to improved glycemic control. It cannot be recommended for metabolic control during olanzapine treatment.

References

  • 1 Ader M, Kim SP, Catalana KJ. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs.  Diabetes. 2005;  54 862-871
    CrossrefPubMedGoogle Scholar
  • 2 Baptista T, Zarate J, Joober R. et al . Drug-induced weight gain: an impediment for successful pharmacotherapy: focus on antipsychotics.  Curr Drug Targ. 2004;  5 279-299
    CrossrefPubMedGoogle Scholar
  • 3 Baptista T, Martinez J, Lacruz A. et al . Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.  Can J Psychiatry. 2006;  51 192-196
    PubMedGoogle Scholar
  • 4 Baptista T, Rangel N, Fernandez V. et al . Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled study.  Schizophr Res. 2007;  93 99-108
    CrossrefPubMedGoogle Scholar
  • 5 Centorrino F, Wurtman JJ, Duca KA. et al . Weight loss in overweight patients maintained on atypical antipsychotic agents.  Int J Obes (Lond). 2006;  30 1011-1016
    CrossrefPubMedGoogle Scholar
  • 6 Chen CH, Chiu CC, Huang MC. et al . Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine.  Prog Neuropsychopharmacol Biol Psychiatry. 2007;  , Nov 17 (Epub ahead of print)
    PubMedGoogle Scholar
  • 7 Hert M De, Kalnicka D, Winkel R Van. et al . Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder.  J Clin Psychiatry. 2006;  67 1889-1896
    PubMedGoogle Scholar
  • 8 Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia.  Cochrane Database Syst Rev. 2007;  24 CD005148
    PubMedGoogle Scholar
  • 9 Festa A, D’Agostino Jr R, Mykkanen L. et al . Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance: the Insulin Resistance Atherosclerosis Study (IRAS).  Arterioscler Thromb Vasc Biol. 1999;  19 562-568
    PubMedGoogle Scholar
  • 10 Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis.  Drug Saf. 2006;  29 303-319
    CrossrefPubMedGoogle Scholar
  • 11 Goldberg RB, Kendall DM, Deeg MA. et al . A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.  Diabetes Care. 2005;  28 1547-1554
    CrossrefPubMedGoogle Scholar
  • 12 Goldberg RB. Impact of thiazolidenediones on serum lipoprotein levels.  Atheroscler Rep. 2006;  8 397-404
    CrossrefPubMedGoogle Scholar
  • 13 Haffner S, Temprosa M, Crandall J. et al . Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance.  Diabetes. 2005;  54 1566-1572
    CrossrefPubMedGoogle Scholar
  • 14 Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.  Drug Saf. 2007;  30 1127-1142
    CrossrefPubMedGoogle Scholar
  • 15 Houseknecht KL, Robertson AS, Zavadoski W. et al . Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects.  Neuropsychopharmacology. 2007;  32 289-297
    CrossrefPubMedGoogle Scholar
  • 16 Isley WL. Hepatotoxicity of thiazolidinediones.  Expert Opin Drug Saf. 2003;  2 581-586
    CrossrefPubMedGoogle Scholar
  • 17 Klein DJ, Cottingham EM, Sorter M. et al . A randomized, double-blind, placebo-controlled trial of metform in treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents.  Am J Psychiatry. 2006;  163 2072-2079
    CrossrefPubMedGoogle Scholar
  • 18 Lieberman JA, Stroup TS, MacEvoy JP. et al . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.  N Engl J Med. 2005;  353 1209-1223
    CrossrefPubMedGoogle Scholar
  • 19 Matthews DR, Hosker JP, Rudenski AS. et al . Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
    Google Scholar
  • 20 MacIntyre RS, Soczynska JK, Lewis GF. et al . Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunities.  Expert Opin Pharmacother. 2006;  7 1305-1321
    CrossrefPubMedGoogle Scholar
  • 21 Menza M, Vreeland B, Minsky S. et al . Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program.  J Clin Psychiatry. 2004;  65 471-477
    PubMedGoogle Scholar
  • 22 Newcomer J. Medical risk in patients with bipolar disorder and schizophrenia.  J Clin Psychiatry. 2006;  67 ((Suppl 9)) 25-30
    PubMedGoogle Scholar
  • 23 Newcomer J. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.  J Clin Psychiatry. 2007;  68 ((Suppl 1)) 20-27
    Google Scholar
  • 24 Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.  N Engl J Med. 2007;  356 2457-2471
    CrossrefPubMedGoogle Scholar
  • 25 Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside.  Kidney Int. 2006;  70 1223-1233
    CrossrefPubMedGoogle Scholar
  • 26 Sarafidis PA, Nilsson PM. The effects of thiazolidinediones on blood pressure levels – a systematic review.  Blood Press. 2006;  15 135-150
    CrossrefPubMedGoogle Scholar
  • 27 Schaefer M, Leopold K, Hinzpeter A. et al . Memantine-associated reversal of clozapine-induced weight gain.  Pharmacopsychiatry. 2006;  39 171-174
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Scheen AJ. Pharmacokinetic interactions with thiazolidinediones.  Clin Pharmacokinet. 2007;  46 1-12
    CrossrefPubMedGoogle Scholar
  • 29 Slama G, Eschwege E, Bernard MH. et al . One-year follow-up in real clinical practice conditions of type 2 diabetic patients treated with rosiglitazone: The Avantage study.  Ann Endocrinol (Paris). Date: 2008 Feb 1;  , [in press]
    PubMedGoogle Scholar
  • 30 Sowell MO, Mukhopadhyay N, Cavazzoni P. et al . Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.  Clin Endocrinol Metab. 2002;  87 2918-2923
    CrossrefPubMedGoogle Scholar
  • 31 Spitzer RL, Williams JBW, Gibbon M. et al . The Structured Clinical Interview for DSM-III-R (SCID), I: history, rationale, and description.  Arch Gen Psychiatry. 1992;  49 624-429
    PubMedGoogle Scholar
  • 32 Vasudevan AR, Balasubramanyam A. Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability.  Diabetes Technol Ther. 2004;  6 850-863
    CrossrefPubMedGoogle Scholar
  • 33 Wellington K. Rosiglitazone/metformin.  Drugs. 2005;  65 1581-1592
    CrossrefPubMedGoogle Scholar
  • 34 Wu RR, Zhao JP, Guo XF. et al . Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.  Am J Psychiatry. Date: 2008 Feb 1;  , (Epub ahead of print)
    PubMedGoogle Scholar
  • 35 Yilmaz H, Gursoy A, Sahin M. et al . Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes.  Acta Diabetol. 2007;  44 187-192
    CrossrefPubMedGoogle Scholar

Correspondence

Prof. T. BaptistaMD, PhD 

Department of Physiology

Los Andes University Medical School

P.O. Box 93

Mérida 5101-A

Venezuela

Phone: +58/274/240 31 10

Fax: +58/274/263 63 95

Email: trinbap@yahoo.com

      >